Sign in

Rick

Managing Director and Senior Equity Research Analyst at Cantor Fitzgerald

Rick is a Managing Director and Senior Equity Research Analyst at Cantor Fitzgerald, focusing on the biotechnology and life sciences sectors. He provides coverage on leading companies such as Eli Lilly, Vertex Pharmaceuticals, and Regeneron, consistently delivering high-performing stock recommendations with a success rate near 65% and top-quartile ranking on TipRanks for returns generated. Rick began his analyst career in the early 2000s at Lehman Brothers and later held senior roles at firms including Jefferies before joining Cantor Fitzgerald in 2015. He holds Series 7, 63, and 86/87 securities licenses, is FINRA-registered, and has been recognized for his detailed industry insights and investment acumen.

Rick's questions to ABEONA THERAPEUTICS (ABEO) leadership

Question · Q3 2025

Rick asked about the planned December plant shutdown for routine maintenance, including its timeline for reopening, and whether any biopsies collected before the temporary pause were not yet sent to manufacturing, requiring potential re-biopsy.

Answer

CEO Vishwas Seshadri confirmed the shutdown from mid-December to early January for mandated FDA maintenance and recalibrations. SVP, Chief Technical Officer, and Chief Scientific Officer Brian Kevany reiterated the schedule. Vishwas Seshadri clarified that no biopsies were collected but not sent to manufacturing during the pause, as the company proactively halted collections to avoid patient inconvenience until the assay issue was resolved.

Ask follow-up questions

Fintool

Fintool can predict ABEONA THERAPEUTICS logo ABEO's earnings beat/miss a week before the call